Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib in advanced pancreatic cancer
NCT05257122Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Feb 2022
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib in pancreatic adenocarcinoma (PDAC), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05257122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05257122.